Tuberculosis Vaccines and Host-Directed Therapies
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Tropical and other Infectious Diseases".
Deadline for manuscript submissions: closed (30 November 2024) | Viewed by 4540
Special Issue Editor
Interests: innate and adaptive immunity; innate lymphoid cells; vaccine induced immunity; infectious diseases; cardiac diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Tuberculosis is a major cause of morbidity and disease. Despite the existence of the Bacille Calmette Guerin (BCG) vaccine and drug regimens, the global epidemic of tuberculosis continues to grow. It is important to develop new and effective vaccines to end the epidemic. While the BCG vaccine effectively prevents childhood pulmonary tuberculosis, its efficacy in adults varies. As a result, the World Health Organization and TB researchers are working to develop better alternatives to reduce the risk of tuberculosis. In this Special Issue, we will discuss the latest developments in TB vaccine research, including advanced studies on the mechanism of the BCG vaccine, challenges in developing better vaccines, and potential new vaccines and promising host-directed therapies.
Dr. Shibali Das
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tuberculosis
- BCG
- M72
- adjuvants
- clinical trials
- animal models
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
